Charles France, Ph.D.
Robert A. Welch Distinguished University Chair in Chemistry, Professor of Pharmacology, and Professor of Psychiatry
Research in the France laboratory focuses on interactions between behavior and pharmacology and how those interactions impact the abuse liability of drugs. One major goal is to understand how the subjective and other abuse-related effects of drugs change as a consequence of particular behavioral and pharmacologic histories. Behavioral procedures developed in this laboratory permit systemic investigation of drug dependence and withdrawal and ongoing studies examine how these phenomena can be modified by behavioral and pharmacologic interventions. A unifying theme of research in the France laboratory is the application of receptor theory to the planning, execution, and interpretation of behavioral pharmacological studies. Thus, many of our studies examine differences in efficacy and selectivity among potential drugs of abuse and potential treatment compounds, thereby identifying the pharmacologic characteristics of drugs that are most important for specific behavioral effects (e.g., reinforcing effects). Current areas of research include the following: the role of different monoamine systems in modifying the abuse and therapeutic effects of opioids; the impact of different diets on the abuse and therapeutic effects of drug acting on serotonin or dopamine systems; interactions between GHB and other “club drugs”; the role of insulin receptor pathways in regulating dopamine transporter activity and sensitivity to stimulants; GABA receptor heterogeneity and the dependence liability of sedative/hypnotics; and the influence of physical dependence on the reinforcing effects of opioids.
Ph.D., University of Michigan
|• drug abuse||• opioids|
|• benzodiazepines||• neuropharmacology|
|• drug discrimination||• self administration|
|• dependence||• withdrawal|
Postdoctoral Training in Drug Abuse Research: Behavior & Neurobiology
Behavior, Biology, and Chemistry: Translational Research in Addiction
A novel opioid receptor antagonist for treating abuse and overdose
Methocinnamox (MCAM): A novel ÃÂµ-opioid receptor antagonist for opioid use disorders
Discriminative Stimulus Effects of Opioid Withdrawal
Awards & Accomplishments
President (Elect, 2019-2020; Current, 2020-2021) – American Society for Pharmacology and Experimental Therapeutics (ASPET) Director, Addiction Research, Treatment and Training Center of Excellence (ARTT)
American Society for Pharmacology and Experimental Therapeutics Addiction Research, Treatment and Training Center of Excellence American College of Neuropsychopharmacology American Society for Pharmacology and Experimental Therapeutics American Psychological Association Behavioral Pharmacology Society College on Problems of Drug Dependence Society for Neuroscience Society for Stimulus Properties of Drugs Texas Research Society on Alcoholism
|Lawrence M. Carey, Ph.D., Postdoctoral Fellow||Cindal C. Dominguez, Med, MBA, Manager, Research Operations|
|Julia Taylor, Laboratory Supervisor|
|Jacob Tovar, Research Assistant|
Countermeasures for Preventing and Treating Opioid Overdose.
Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors.
Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.
Effects of remifentanil/histamine mixtures in rats responding under a choice procedure.
Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone.
Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.
Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.
Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.
Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys.
OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.
Impact of order of fixed-ratio presentation on demand for self-administered remifentanil in male rats.
Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats.
Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys.
Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist.
Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.
Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys.
Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys.
Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.
Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of µ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats.
Effects of daily methocinnamox treatment on fentanyl self-administration in rhesus monkeys.
Effects of amphetamine, methylphenidate, atomoxetine, and morphine in rats responding under an adjusting stop signal reaction time task.
Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.
Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence.
Characterization of the Discriminative Stimulus Effects of Binary Mixtures of Mu Opioid Receptor Agonists in Rats Discriminating Fentanyl.